Key statistics
On Friday, BeOne Medicines AG (49BA:FRA) closed at 264.00, -18.01% below its 52-week high of 322.00, set on Nov 13, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 258.00 |
|---|---|
| High | 264.00 |
| Low | 258.00 |
| Bid | 264.00 |
| Offer | 272.00 |
| Previous close | 272.00 |
| Average volume | 55.30 |
|---|---|
| Shares outstanding | 118.51m |
| Free float | 21.45m |
| P/E (TTM) | 126.05 |
| Market cap | 39.38bn USD |
| EPS (TTM) | 2.51 USD |
Data delayed at least 15 minutes, as of Feb 27 2026 14:43 GMT.
More ▼
Press releases
- BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership
- BeOne Medicines to Present at Upcoming Investor Conferences
- BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26
- BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
- ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA
- BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
- BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma
- BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
- Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies
More ▼
